Skip to main navigation Skip to main content

CEEM : Clinical and Experimental Emergency Medicine

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Editorial

Management of breakthrough cancer pain in the emergency department

Clinical and Experimental Emergency Medicine 2026;13(3):258-262.
Published online: September 23, 2026

Department of Emergency Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence to: Shin Ahn (ans1023@gmail.com)
• Received: June 17, 2026   • Revised: July 1, 2026   • Accepted: July 12, 2026

Copyright © 2026 The Korean Society of Emergency Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

  • 1,992 Views
  • 36 Download
prev next
Pain is among the most common symptoms in patients with cancer who present to the emergency department (ED) for care [1]. Effective pain management requires an individualized approach that considers the underlying etiology and characteristics of the pain, the patient’s overall clinical condition, and prior opioid exposure, including whether the patient is opioid-naive or opioid-tolerant. Accurate assessment of the pain mechanism and opioid status is essential for achieving adequate pain control.
The World Health Organization analgesic ladder remains the cornerstone of cancer pain management. It classifies pain as mild, moderate, or severe and recommends analgesic escalation according to pain intensity. Although the ladder has been expanded from three to four steps for refractory pain, its central principle remains stepwise progression from nonopioid analgesics to weak opioids and then to strong opioids. In opioid-naive patients, mild pain is treated with nonopioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, with or without adjuvant medications, whereas opioids are used for moderate to severe pain. Traditionally, weak opioids, such as codeine, hydrocodone, and tramadol, were recommended before strong opioids, such as morphine, oxycodone, and hydromorphone. However, evidence has shown that low-dose morphine provides faster and more effective analgesia than weak opioids without increasing adverse events [2]. Accordingly, the second step of the ladder is now considered optional, allowing direct transition from nonopioid analgesics to strong opioids when clinically appropriate [3].
Breakthrough pain is defined as a transient exacerbation of pain that occurs despite relatively well-controlled baseline pain and stable analgesic therapy. In opioid-naive patients, breakthrough pain should be managed with low-dose morphine, given as 2 to 5 mg intravenously or 5 to 15 mg orally, or with an equianalgesic alternative. Opioid-tolerant patients should receive rescue doses equivalent to 10%–20% of their total daily opioid dose [4]. Despite this dosing recommendation, adequate analgesia is often not achieved in the ED. Emergency physicians may have limited experience in cancer pain management, and concern about opioid overmedication may contribute to undertreatment [5]. In a retrospective study of patients with cancer who presented to the ED with acute pain, only 3.2% of patients with high opioid requirements received an adequate breakthrough dose [6]. Similarly, in our experience, patients who routinely require high-dose opioids are often prescribed insufficient doses of morphine in the ED; for example, 5 mg of intravenous morphine may be administered regardless of the patient’s baseline opioid requirement. This conventional dose may be insufficient to suppress breakthrough pain, particularly in patients with high baseline opioid requirements. Although fear of respiratory depression may discourage appropriate opioid escalation, long-term opioid therapy can lead to tolerance not only to analgesic effects but also to opioid-related adverse effects, including respiratory depression. In addition, pain itself may further blunt respiratory depressive effects [7]. Therefore, these concerns should not deter clinically indicated opioid titration in patients receiving long-term opioid therapy. To ensure appropriate rescue dosing, emergency physicians should routinely assess the patient’s total opioid dose during the preceding 24 hours and apply equianalgesic conversions (Table 1).
After opioid administration, analgesic efficacy should be reassessed every 15 minutes after intravenous dosing and every 60 minutes after oral dosing to determine whether additional medication is needed. Based on the clinical response, the rescue dose should be adjusted as follows: increased by 50% to 100% if pain is unchanged or worsening, repeated at the same dose if relief is partial but inadequate, or continued at the current dose on an as-needed basis once pain is adequately controlled. In cases of pain crisis or refractory breakthrough pain, hospital admission may be necessary to allow rapid opioid titration and symptom stabilization (Fig. 1).
Patients discharged from the ED after pain stabilization must receive appropriate education on opioid use and dose titration. Long-acting opioids should be administered on a scheduled, around-the-clock basis rather than as needed, with short-acting opioids used for rescue dosing. If analgesia remains inadequate, the rescue dose may be increased by 30% to 100%. Conversely, persistent reliance on multiple rescue doses should prompt a corresponding increase in the long-acting opioid dose. Clinicians should also consider adjuvant analgesics, specialty consultation, or opioid rotation when adverse effects limit dose escalation. Ongoing reassessment is essential, and tools such as pain diaries may help guide postdischarge dose adjustments.
Nonopioid analgesics
Acetaminophen and NSAIDs remain important adjuncts in cancer pain management, although their clinical utility is limited by specific toxicity profiles. Acetaminophen has limited efficacy at high pain intensities; to avoid hepatotoxicity in chronic users, the daily dose should not exceed 3 g, particularly in older adults. In addition, recent evidence has raised concern that concomitant acetaminophen administration may reduce the efficacy of immune checkpoint inhibitors, leading to blunted tumor responses and shorter survival times [8]. NSAIDs are effective for inflammatory and bone pain but require systematic assessment of gastrointestinal, renal, and cardiovascular risks. To reduce the risk of upper gastrointestinal bleeding, clinicians should evaluate age, history of peptic ulcer disease or bleeding, and concurrent steroid or anticoagulant use. The risk of renal toxicity requires particular caution in patients with volume depletion, renal insufficiency, or concurrent exposure to nephrotoxic agents or renally excreted chemotherapeutic drugs. When cardiovascular toxicity is a concern, NSAIDs should be discontinued if congestive heart failure or hypertension develops or worsens. For localized peripheral joint pain, topical NSAIDs provide an effective alternative with less systemic exposure.
Adjuvant analgesics, including anticonvulsants, antidepressants, corticosteroids, and topical agents, are essential for managing cancer-related pain, particularly neuropathic and bone pain. In a randomized trial, pregabalin relieved neuropathic pain more effectively than transdermal fentanyl [9]. Corticosteroids provide additional benefit for neuropathic pain, bone pain, and malignant bowel obstruction through anti-inflammatory mechanisms [10]. Although the evidence is insufficient to support specific regimens, a meta-analysis demonstrated that adding antidepressants or anticonvulsants to opioids improved pain control compared with opioid monotherapy [11]. For localized neuropathic pain, topical lidocaine patches or topical NSAIDs are viable options.
Opioids
Pure opioid agonists, including morphine, oxycodone, hydromorphone, and fentanyl, remain the mainstay of cancer pain management. Short-acting formulations are preferred for acute pain because they can be titrated rapidly according to the patient’s analgesic response.
Morphine remains the standard first-line opioid for opioid-naive patients. In the ED, patients with severe pain who require rapid relief should receive parenteral opioids, administered intravenously or subcutaneously; the equivalent intravenous dose is approximately one-third of the oral dose.
Fentanyl, a highly lipophilic opioid, is available in parenteral, transmucosal, and transdermal formulations. Transdermal fentanyl is unsuitable for rapid titration and is indicated only for opioid-tolerant patients whose pain has already been adequately controlled. This route is particularly useful for patients who cannot swallow and for those with poor adherence to oral therapy. Compared with oral morphine, transdermal fentanyl has been associated with lower rates of constipation and other opioid-related adverse effects [12,13]. Rapid-onset transmucosal fentanyl formulations, such as buccal or sublingual tablets, intranasal sprays, and soluble films, are also important options for managing breakthrough pain in opioid-tolerant patients.
Hydromorphone and oxycodone are appropriate first-line alternatives to morphine and have comparable analgesic efficacy. Hydromorphone should be used with caution in patients at risk for opioid-induced neurotoxicity because its metabolites may contribute to myoclonus, hyperalgesia, and seizures [14]. Oxycodone has a safety and efficacy profile similar to that of morphine, and combination formulations containing naloxone may reduce opioid-induced constipation during long-term treatment [15].
Tramadol and tapentadol are atypical opioids that combine mu-opioid receptor agonism with central norepinephrine reuptake inhibition, which may provide benefit for neuropathic pain. Tramadol, a weak opioid, is associated with a high incidence of adverse effects, including nausea, vomiting, dizziness, and weakness [16]. Evidence supporting tramadol for cancer pain is limited, and tramadol is less effective than morphine [17]. In contrast, tapentadol is approved for moderate to severe pain and can treat both nociceptive and neuropathic pain, with fewer gastrointestinal adverse effects than traditional opioids [18]. It has therefore been considered a useful option for cancer pain management. Tapentadol appears to be safe in patients with hepatic impairment and may be particularly beneficial for mixed pain etiologies, including hematologic malignancies, bone metastases, and chemotherapy-induced pain.
Buprenorphine, a partial opioid agonist with mixed agonist and antagonist properties, is approved for chronic pain. Although it is not typically used as a first-line analgesic for cancer pain, the 5-μg/hr transdermal formulation is suitable for opioid-naive patients who require long-acting therapy. Because of its ceiling effect on respiratory depression, lower misuse potential, minimal tolerance development, and reduced constipation, buprenorphine may offer favorable tolerability and safety compared with full opioid agonists. Consequently, it may be preferred for patients who are sensitive to opioid-related adverse effects and is also approved for opioid withdrawal and maintenance treatment for opioid dependence. Furthermore, because buprenorphine undergoes extensive hepatic metabolism and biliary excretion, it is advantageous in patients with renal impairment, as neither the parent drug nor its active metabolites accumulate substantially [19].
Despite its high prevalence and clinical significance, cancer pain management in the ED remains overly conservative. Intravenous morphine continues to be a key option for acute pain management in the ED; however, dosing should be individualized according to prior opioid exposure and the patient’s clinical response. Improving clinical awareness, educating frontline providers, and implementing ED-specific institutional pain management protocols may support more consistent pain control and safer opioid titration.

Conflicts of interest

Shin Ahn is a section editor of this journal, but was not involved in the peer reviewer selection, evaluation, or decision process of this article. The author has no other conflicts of interest to declare.

Funding

The author received no financial support for this study.

Data availability

Data sharing is not applicable as no new data were created or analyzed in this study.

Fig. 1.
Emergency department management of cancer pain. a)After adequate pain control has been achieved, ongoing care, including discharge education and routine follow-up for reassessment and opioid tapering, should be provided.
ceem-26-308f1.jpg
Table 1.
Opioid equianalgesic conversion table
Table 1.
Opioid Drug dosage Duration
Morphine IV: 10 mg IV; 3–4 hr
Oral: 30 mg Oral IR, 4 hr
SR; 8–12 hr
Oxycodone Oral: 20 mg IR; 4 hr
SR; 12 hr
Hydromorphone IV: 1.5 mg IR; 4 hr
Oral: 7.5 mg SR; 12 hr
Tapentadol Oral: 100 mg IR; 4 hr
SR; 12 hr
Fentanyl patch 12.5 μg/hr 3 days
Transmucosal fentanyl 200 μg
 Buccal/sublingual tablet Onset: 10–15 min 4 hr
 Intranasal spray Onset: 5–10 min 1 hr
Buprenorphine patch 5-μg/hr patch (=12 mg/day oral morphine) 7 days

The equianalgesic doses listed above are expressed relative to 30 mg of oral morphine. However, for the buprenorphine transdermal patch, a dose of 5 μg/hr is considered equianalgesic to 12 mg/day of oral morphine.

IV, intravenous; IR, immediate release; SR, sustained release.

  • 1. Alishahi Tabriz A, Turner K, Hong YR, Gheytasvand S, Powers BD, Elston Lafata J. Trends and characteristics of potentially preventable emergency department visits among patients with cancer in the US. JAMA Netw Open 2023;6:e2250423.
  • 2. Bandieri E, Romero M, Ripamonti CI, et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 2016;34:436-42.
  • 3. Fallon M, Dierberger K, Leng M, et al. An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer. Ann Oncol 2022;33:1296-303.
  • 4. Swarm RA, Youngwerth JM, Agne JL, et al. Adult cancer pain, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2025;23:e250032.
  • 5. Young A, Marshall E, Krzyzanowska M, et al. Responding to acute care needs of patients with cancer: recent trends across continents. Oncologist 2016;21:301-7.
  • 6. Patel PM, Goodman LF, Knepel SA, et al. Evaluation of emergency department management of opioid-tolerant cancer patients with acute pain. J Pain Symptom Manage 2017;54:501-7.
  • 7. Bateman JT, Saunders SE, Levitt ES. Understanding and countering opioid-induced respiratory depression. Br J Pharmacol 2023;180:813-28.
  • 8. Bessede A, Marabelle A, Guégan JP, et al. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Ann Oncol 2022;33:909-15.
  • 9. Raptis E, Vadalouca A, Stavropoulou E, Argyra E, Melemeni A, Siafaka I. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract 2014;14:32-42.
  • 10. Wooldridge JE, Anderson CM, Perry MC. Corticosteroids in advanced cancer. Oncology (Williston Park) 2001;15:225-34.
  • 11. Guan J, Tanaka S, Kawakami K. Anticonvulsants or antidepressants in combination pharmacotherapy for treatment of neuropathic pain in cancer patients: a systematic review and meta-analysis. Clin J Pain 2016;32:719-25.
  • 12. Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev 2013;2013:CD010270.
  • 13. Wang DD, Ma TT, Zhu HD, Peng CB. Transdermal fentanyl for cancer pain: trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Cancer Res Ther 2018;14(Supplement):S14-21.
  • 14. Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409-20.
  • 15. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60.
  • 16. Rodriguez RF, Bravo LE, Castro F, et al. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med 2007;10:56-60.
  • 17. Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev 2017;5:CD012508.
  • 18. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30:489-505.
  • 19. Böger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med 2006;20 Suppl 1:s17-23.

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Management of breakthrough cancer pain in the emergency department
Clin Exp Emerg Med. 2026;13(3):258-262.   Published online September 23, 2026
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Management of breakthrough cancer pain in the emergency department
Clin Exp Emerg Med. 2026;13(3):258-262.   Published online September 23, 2026
Close

Figure

  • 0
Management of breakthrough cancer pain in the emergency department
Image
Fig. 1. Emergency department management of cancer pain. a)After adequate pain control has been achieved, ongoing care, including discharge education and routine follow-up for reassessment and opioid tapering, should be provided.
Management of breakthrough cancer pain in the emergency department
Opioid Drug dosage Duration
Morphine IV: 10 mg IV; 3–4 hr
Oral: 30 mg Oral IR, 4 hr
SR; 8–12 hr
Oxycodone Oral: 20 mg IR; 4 hr
SR; 12 hr
Hydromorphone IV: 1.5 mg IR; 4 hr
Oral: 7.5 mg SR; 12 hr
Tapentadol Oral: 100 mg IR; 4 hr
SR; 12 hr
Fentanyl patch 12.5 μg/hr 3 days
Transmucosal fentanyl 200 μg
 Buccal/sublingual tablet Onset: 10–15 min 4 hr
 Intranasal spray Onset: 5–10 min 1 hr
Buprenorphine patch 5-μg/hr patch (=12 mg/day oral morphine) 7 days
Table 1. Opioid equianalgesic conversion table

The equianalgesic doses listed above are expressed relative to 30 mg of oral morphine. However, for the buprenorphine transdermal patch, a dose of 5 μg/hr is considered equianalgesic to 12 mg/day of oral morphine.

IV, intravenous; IR, immediate release; SR, sustained release.